At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

High salt concentrations are present in the affected skin of people with atopic dermatitis and promote the differentiation of the T helper cells involved in the development of allergic diseases.

Belly fat helps fight infection, but is also a common site of metastasis.

Brief electroporation appears to make T cells more receptive to new genetic material, which could speed the development of immunotherapies.

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

Emerging technologies help researchers draw mechanistic links between metabolism and epigenetic modification of DNA.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

A small clinical trial demonstrates that peptide immunotherapy can halt the progression of early-stage type 1 diabetes.